Area of research
Pathology and Forensic Medicine · Oncology
Research interest
The laboratory's research is directed toward elucidating and understanding the molecular mechanisms underlying the pathogenesis of lymphomas, and in using this information to develop rational methods for classification and prognostication. ALCL, a large cell lymphoma variant that primarily affects children and young adults, is characterized by the t(2;5), which results in inappropriate expression of anaplastic lymphoma kinase (ALK) through its fusion with nucleophosmin (NPM). We have shown that NPM/ALK fusion transcripts are specific to ALCL, and do not occur in other lymphomas, including Hodgkin's disease (HD). We also showed that the immunohistochemical profile of ALCL is different from HD, in that ALCL expresses the cytotoxic granule-associated proteins TIA-1, perforin, and granzyme B.
Molecular, histologic, and clinical characterization of methylation class pleomorphic xanthoastrocytoma: An analysis of 469 tumors
Molecular characteristics and improved survival prediction in a cohort of 2023 ependymomas
Data from Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest
High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13
Molecular and clinicopathologic characteristics of gliomas with EP300::BCOR fusions
Recurrent ACVR1 mutations in posterior fossa ependymoma
CCL5 production in lung cancer cells leads to an altered immune microenvironment and promotes tumor development
Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy
The Genetic Basis of Hepatosplenic T-cell Lymphoma
Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer
Chromothriptic Cure of WHIM Syndrome
Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest
Succinate Dehydrogenase Mutation Underlies Global Epigenomic Divergence in Gastrointestinal Stromal Tumor
Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations.